Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Celebrex PRECISION Trial: 'Herculean' Effort, But Missing Information Bugs US FDA Panel

Apr 29 2018

• By Brenda Sandburg

FDABldg1ExteriorWithCircle_1200x675

Related Content

Celebrex Likely To Get Label Change Saying CV Risk Is Comparable To Ibuprofen, Naproxen

Apr 26 2018

Related Companies

Pfizer Inc.

Merck & Co., Inc.

Additional Topics

United States Advisory Committees Drug Safety Regulation Inflammation BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window